Sichuan Goldstone: Announcement of Annual Equity Distribution Implementation in 2023
Sichuan Goldstone: Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders
Sichuan Goldstone: Legal Opinion on the 2023 Annual General Meeting of Shareholders of Sichuan Jinshi Asia Pharmaceutical Co., Ltd.
Sichuan Goldstone: 300434 Jinshi Asia Pharmaceutical Investor Relations Management Information 20240517
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Liu Chuwang)
Sichuan Goldstone: Announcement on the proposed renewal of financial auditors and internal control auditors in 2024
Sichuan Goldstone: Announcement of Board Resolutions
Sichuan Goldstone: Announcement on holding the 2023 online results briefing
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhu Jianwei)
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Miao Jianquan)
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhao Xiaowei)
Sichuan Goldstone: Assessment report on the recoverable value assets of the asset group portfolio involved in the proposed impairment test of goodwill formed by merging Hainan Asia Pharmaceutical Co., Ltd.
Sichuan Goldstone: 2023 Independent Director Debriefing Report (Zhong Peng)
Sichuan Goldstone: The Board's special opinion on the sole director's independence assessment
Sichuan Goldstone: Announcement on preparation for impairment of assets accrued in 2023
Sichuan Goldstone: Announcement of Supervisory Board Resolutions
Sichuan Goldstone: Announcement on the appointment of a representative for securities affairs
Sichuan Goldstone: Asset group recyclable value asset assessment report involved in the proposed impairment test of goodwill formed by merging Zhejiang Jiande Zhengfa Pharmaceutical Co., Ltd.
Sichuan Goldstone: Goodwill impairment test report
Sichuan Goldstone: Special report on the occupation of non-operating capital and other related capital transactions
No Data